RxDoctor Payments Data

Anthony Smith, MD

Family Medicine · Augusta, GANPI 1740267194

Payments from drug & device makers

$15,077in general payments, 2019–2025

Across 933 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Pfizer$978
  • Lilly USA, LLC$933
  • Amarin Pharma, Inc.$839
  • plus $7K from 48 others

What the payments were for

  • Food & beverage$15,039100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,077 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$105,950
Medicare patients
242
Services billed
2,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$114,144
JardianceEmpagliflozin39$51,724
JanuviaSitagliptin Phosphate29$46,937
FarxigaDapagliflozin Propanediol58$43,507
OzempicSemaglutide38$36,119
MounjaroTirzepatide28$35,119
Soliqua 100-33Insulin Glargine/Lixisenatide20$22,322
XareltoRivaroxaban20$20,850
RybelsusSemaglutide13$20,569
Tresiba Flextouch U-100Insulin Degludec20$14,124
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,508
VascepaIcosapent Ethyl12$10,840
MyrbetriqMirabegron20$9,571
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,664
Rosuvastatin Calcium329$3,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$978$114,144100 claims
Novo NordiskOzempic, Rybelsus$2,529$56,68851 claims
Boehringer IngelheimJardiance$699$51,72439 claims
MerckJanuvia$88$46,93729 claims
AstraZenecaFarxiga$1,512$43,50758 claims
Lilly USA, LLCMounjaro$933$35,11928 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$497$22,32220 claims
Johnson & JohnsonXarelto$159$20,85020 claims
GSKTrelegy Ellipta$670$12,50813 claims
Astellas Pharma US IncMyrbetriq$193$9,57120 claims
AbbVieSynthroid$1,646$1,41516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →